Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 | |
FC (functional) | = 0.816 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 5 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
FC (functional) | = 0.821 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 0.1 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
FC (functional) | = 0.885 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 1 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
FC (functional) | = 1.248 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 10 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
FC (functional) | = 1.635 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 25 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
FC (functional) | = 2.225 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 50 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
FC (functional) | = 3.41 | Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 100 uM after 24 hrs by dual-luciferase assay relative to control | ChEMBL. | 22472691 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.